| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$28.8M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $94.5M | Trading Days | 2047 |
| 52W High | 1.51 |
| 52W Low | 0.77 |
| % Off High | −47.54% |
| YTD | −8.95% | 1Y | −27.33% |
| 3Y | −71.81% | 5Y | −67.00% |
| Since incept. (ann.) | −22.14% |
| Ann. Volatility (1Y) | 88.79% | Ann. Volatility (3Y) | 83.20% |
| Sharpe (1Y) | 0.06 | Sharpe (3Y) | −0.11 |
| Max Drawdown (1Y) | −45.42% | Max Drawdown (3Y) | −88.16% |
| Beta (3Y, vs SPY) | 1.14 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| COYA | Coya Therapeutics, Inc. | $93.8M | — |
| ALDX | Aldeyra Therapeutics, Inc. | $95.3M | — |
| PLYX | Polaryx Therapeutics, Inc. | $92.8M | — |
| VRCA | Verrica Pharmaceuticals Inc. | $92.8M | — |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $92.0M | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $90.8M | — |
| BMEA | Biomea Fusion, Inc. | $90.4M | — |
| IXHL | Incannex Healthcare Inc. | $102.0M | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $102.0M | — |
| OGI | ORGANIGRAM GLOBAL INC. | $103.0M | — |
| RLYB | Rallybio Corp |
| $85.6M |
| — |
| GNPX | Genprex, Inc. | $85.0M | — |
